RCS - Medpal AI PLC - CEO Interview on Vox Markets

Medpal AIAnnouncement

09/12/2025 08:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251209:nRSI8063Ka&default-theme=true

RNS Number : 8063K  Medpal AI PLC  09 December 2025

 

9 December 2025

RNS REACH

 

MedPal AI Plc

("MedPal AI" or the "Company")

 

CEO Interview Published on Vox Markets

 

MedPal AI plc (AIM: MPAL), the UK-based digital health and artificial
intelligence company, is pleased to announce the publication of a feature
interview with Chief Executive Officer Jason Drummond on Vox Markets, one of
the UK's leading platforms for retail investor engagement.

 

In the interview, Mr. Drummond discusses the Company's recently launched major
upgrade to the MedPal AI wellness app and the strategic rollout of the updated
platform through its partnership with Epassi UK Limited, which provides access
to more than 11 million employees across the UK, including those at Siemens
and Volvo.

 

The discussion highlights the significant AI enhancements introduced in the
latest app release, including a new multimodal AI assistant, test result
upload and interpretation, longitudinal health tracking through memory-based
AI personalisation, and real-time integration with wearable health data. Mr.
Drummond also elaborates on how the app fits into MedPal AI's broader business
model, supporting the Company's automated pharmacy fulfilment platform,
MedPal.clinic.

 

The interview offers investors valuable insights into MedPal's long-term
vision of transforming personalised preventive health through a dual-engine
approach, combining engaging AI-powered wellness tools with scalable clinical
service fulfilment.

 

The full interview can be viewed here:

https://www.voxmarkets.co.uk/articles/medpal-transforming-wellness-ai-epassi-and-the-future-of-preventive-health-804fe1f
(https://www.voxmarkets.co.uk/articles/medpal-transforming-wellness-ai-epassi-and-the-future-of-preventive-health-804fe1f)

 

For further information, please contact:

 MedPal AI plc                       www.medpalplc.com (https://www.medpalplc.com/)

 Jason Drummond

 Clear Capital Markets Limited       +44(0) 20 3869 6080

 Bob Roberts

 Winterflood Retail Access Platform  WRAP@winterflood.com

 Sophia Bechev, Kaitlan Billings     +44(0) 20 3100 0214

 

 

About MedPal AI

MedPal AI is a UK-based digital health company focused on AI-driven wellness
and personalised healthcare. Its flagship app integrates over 100 wearable
devices and health apps to offer individualised lifestyle guidance via a
conversational AI assistant. The Company also operates MedPal.clinic, a 24/7
automated pharmacy platform providing nationwide prescription fulfilment using
advanced robotics and AI triage systems.

 

MedPal AI's partnership with Epassi UK enables free access to its wellness app
for over 11 million employees at major corporates. The Company is also
developing opportunities in B2B licensing and insurance-linked wellness
programmes.

 

Note: This announcement is a non-regulatory RNS Reach disclosure intended to
provide information to investors on media coverage and company developments
that may be of interest.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUKVBRVWUURRA



            Copyright 2019 Regulatory News Service, all rights reserved